Business
TRICCAR Releases Results Of Study Of AVL™ Anti-Viral Supplement
TRICCAR Releases Results Of Study Of AVL™ Anti-Viral Supplement.
About this update from Correlate Energy Corp.
[{"type":"text","content":"\n\n\n\nTRICCAR Releases Results Of Study Of AVL™ Anti-Viral Supplement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTRICCAR Releases Results Of Study Of AVL™ Anti-Viral Supplement\nStudy Reports Reduction in Human Coronavirus, RSV, Rhinovirus and Influenza vs. Placebo\nPR Newswire\nLAS VEGAS, June 10, 2020\n\n\n\nLAS VEGAS, June 10, 2020 /PRNewswire/ -- As the United States and world continue to struggle with the ongoing effects of the COVID-19 pandemic, TRICCAR, Inc. (OTC: FOSI), announces the results of a double-blind placebo-controlled study of AVL™, its proprietary immune-support anti-viral supplement. \n\n \n \n \n \n \n \n\n \n\"The results of this study back up our hypothesis that AVL supports the human immune system and can be a valuable part of a person's wellness regimen,\" said Bill Townsend, President and CEO of TRICCAR, Inc. \nConducted between October 14, 2019 and March 15, 2020, the study included 118 men and women between the ages of 25-80. Participants in the AVL group were given the recommended dosage of two tablets, twice daily. The control participants were given the same dosage of a placebo. The AVL group reported fewer incidents of human coronavirus, Rhinovirus, RSV, and influenza:\nThe study reported that 40.6% of the placebo group became infected with the human coronavirus, RSV, or Rhinovirus compared to 10.5% of those taking AVL. Fewer cases of influenza were reported with 21.4% of those taking placebo contracting the flu, roughly the same number as the general population in a given year. Only 4.7% of those taking AVL tested positive for influenza.   Of the 56 participants who reported catching cold or flu previously in 2018, only nine contracted either in 2019/2020 after taking AVL.\"AVL's results suggest an easy and effective over-the-counter product to help people support their natural defenses against viruses,\" said Townsend. \"This is an important and vital benefit for people as we prepare for the upcoming cold and flu season.\" \nWhile the study did not test for severe acute respiratory syndrome coronavirus 2 (SA...